Humatrope is a drug based on the hormones of the anterior lobe of the pituitary gland (HGH, somatropin). This is a biosynthetic recombinant human growth hormone with 191 amino acid residues in the polypeptide chain. It has somatotropic, anabolic and growth-stimulating effects. The drug stimulates bone growth and causes an increase in the number and size of cells (in muscles, liver, thymus gland, adrenal glands, thyroid gland). This form of somatropin activates the synthesis of collagen, regulates protein metabolism, reduces cholesterol, increases the number of triglycerides, reduces the amount of fat tissue, prevents loss of liquid, nitrogen, sodium, potassium and phosphorus.
Somatropin stimulates linear growth in children with hgh deficiency, as well as in children with growth retardation in Turner syndrome. Treatment of hgh deficiency in children causes an increase in the growth rate. In addition, somatropin enhances intracellular protein synthesis and causes nitrogen retention.
Humatrope indications for use: disorders of the growth process in children with insufficient endogenous growth hormone production, chronic renal failure accompanied by growth disorders (in children), immunodeficiency disorders accompanied by loss of body weight, osteoporosis.
Information regarding Humatrope contraindications
Start studying Humatrope contraindications: hypersensitivity, malignant neoplasms, epiphyseal closure, acute conditions associated with complications after surgery or multiple injuries, pregnancy, breastfeeding.
Caution should be used in patients with diabetes mellitus or patients with predisposition to diabetes. It is necessary to monitor the level of glucose in the blood and urine. Patients with growth hormone deficiency need more frequent examinations to exclude progression and recurrence of tumor growth. Hypothyroidism may develop during the treatment (the effectiveness of therapy may be reduced). A thorough examination of the fundus is recommended to detect swelling of the optic disc (in case of recurring headaches, visual disturbances, nausea, vomiting). It is necessary to stop Humatrope therapy in this case (to exclude symptoms of intracranial hypertension).
It is not known whether recombinant somatropin affects reproductive function or whether it can cause fetal damage when used in pregnant women. Therefore, Humatrope should not be administered during pregnancy.
It is not known whether this drug penetrates into breast milk. Therefore, breastfeeding should be discontinued during Humatrope therapy.
Interaction with other drugs
Glucocorticoids reduce the stimulating effect of Humatrope on growth processes. Adequate doses should be carefully selected to prevent adrenal insufficiency.
Patients diagnosed with diabetes mellitus may need to adjust their doses of insulin or other hypoglycemic agents.
Somatropin can increase the activity of cytochrome P450 isoenzymes (CYPs), which can cause a decrease in concentration and reduce the effectiveness of certain drugs, such as steroid sex hormones, cyclosporins and some anticonvulsants.
Concomitant therapy with other hormonal drugs (for example gonadotropin, anabolic steroids, estrogens and thyroid hormones) is not recommended.
Learn about dosing and administration information for Humatrope
The drug is given by subcutaneous route. Intramuscular injection is allowed as well. The dose should be selected individually (up to 0.48 IU / kg per week).
Doses in case of growth hormone deficiency: up to 0.48 IU / kg per week. Doses in case of Turner syndrome: 0.8-0.9 IU / kg. The weekly dose is divided into 6-7 injections and administered at night. It is necessary to control the concentration of glucose and thyroid hormones in case of long-term therapy.
Learn about the potential side effects of Humatrope
Common and rare side effects include: headache, increased intracranial pressure, frequent headaches, nausea, vomiting, visual impairment, suppression of thyroid function (symptoms of hypothyroidism), hyperglycemia, leukemia, pain and itching at the injection site.
Immune system: hypersensitivity to the components of the drug, including allergic reactions.
Endocrine system: very often - hypothyroidism.
Metabolism: very often - swelling (in adults), hyperglycemia, including impaired glucose tolerance (in adults).
CNS: very often - headache; often - insomnia (in adults), carpal tunnel syndrome, paresthesia (in adults); rarely - benign intracranial hypertension, paresthesia (in children); very rarely - insomnia (in children).
Digestive disorders: rarely - pancreatitis.
Musculoskeletal system: very often - arthralgia (in adults); often - myalgia (in adults), scoliosis (in children); rarely - myalgia (in children).
Genitals and mammary gland: rarely - gynecomastia (in adults); very rarely - gynecomastia (in children).
General disorders: often - pain at the injection site; rarely - weakness, glucosuria (in adults); very rarely - glucosuria (in children).
Metabolism: rarely - type 2 diabetes mellitus (in children).
Vascular disturbances: often - high blood pressure (in adults); very rarely - high blood pressure (in children).
Respiratory system: often - dyspnea (in adults).
There are reports that a small number of children treated with somatropin (including Humatrope) suffered from leukemia. The direct relationship between leukemia and treatment with somatropin is still unclear.
Symptoms of prolonged toxicity (overdose): gigantism and acromegaly, growth hormone hypersecretion, hypo- or hyperglycemia. Acute overdose can lead first to hypoglycemia, and then to hyperglycemia. Chronic overdose can cause signs and symptoms of gigantism or acromegaly.
Special instructions related to Humatrope therapy
Humatrope therapy should be conducted by doctors with experience in diagnosing and treating patients with GH deficiency or with Turner syndrome.
Intracranial neoplasm. More frequent examinations are recommended for patients with GH deficiency that occurred in the presence of neoplasms of the brain (to exclude the progression and relapse of the disease). Somatropin should not be used if there is any sign of active growth of the tumor. Antitumor therapy must be completed before you start taking Humatrope. The drug should be discontinued if signs of tumor growth appear.
Intracranial hypertension. Examination of the fundus is recommended in the case of severe or recurrent headaches, visual impairment, nausea or vomiting (to exclude edema of the optic nerve disk and intracranial hypertension). It is necessary to stop treatment with somatropin in this case.
Hypopituitarism/Hypothyroidism. Patients with hypopituitarism (deficiency of certain pituitary hormones) should be under strict supervision in the case of standard hormonal replacement therapy with somatropin. Note that hypothyroidism may occur during treatment with Humatrope.
Diabetes mellitus. Humatrope can cause insulin resistance. Therefore, patients should be monitored to identify signs of impaired glucose tolerance. Patients with diabetes mellitus should be under constant medical supervision. It may be necessary to adjust the dose of insulin during treatment with somatropin.
Elderly patients. Elderly patients are more sensitive to somatropin. Therefore, the risk of side effects is higher. It is advisable to use a smaller starting dose.
Obesity. The risk of adverse events is higher in patients with obesity.
Leukemia. A small group of children on GH therapy (including those using Humatrope) suffered from leukemia. The direct relationship between leukemia and Humatrope therapy has not been established.
Scoliosis in children. Scoliosis is often diagnosed in children on GH therapy. Somatropin promotes bone growth. Therefore, patients using Humatrope should be monitored for progression of scoliosis.
The risk of pancreatitis is higher in children who are on therapy with somatropin.
Somatropin therapy should only be prescribed by physicians with experience in treating children with growth disorders and adults with GH deficiency.